GLP1R and hydrops fetalis: The completed CVOTs have evaluated the cardiovascular safety of dipeptidyl-peptidase 4 inhibitors (DPP4i), glucagon-like peptide-1 receptor agonists (GLP1-RA) and sodium-glucose transporter 2 inhibitors (SGLT2i) in T2D patients at risk for HF.